SARS-CoV-2 serologic surveillance among people living with HIV in Nigeria, April 2022 to January 2023.

IF 4.8 2区 医学 Q1 INFECTIOUS DISEASES
Helen M Chun, Sophia Osawe, Samuel Adams-Dabban, Jennifer Favaloro, Nnaemeka C Iriemenam, Emilio Dirlikov, Diana Martin, Kyle Milligan, Andrew Abutu, Olumide Okunoye, Mary Okoli, Olusola Akanbi, Oluwaseun Akinmulero, Rita Okonkwo, Oyewole Oyedele, Stacie Greby, Alash'le Abimiku, McPaul I J Okoye, Ray W Shiraishi
{"title":"SARS-CoV-2 serologic surveillance among people living with HIV in Nigeria, April 2022 to January 2023.","authors":"Helen M Chun, Sophia Osawe, Samuel Adams-Dabban, Jennifer Favaloro, Nnaemeka C Iriemenam, Emilio Dirlikov, Diana Martin, Kyle Milligan, Andrew Abutu, Olumide Okunoye, Mary Okoli, Olusola Akanbi, Oluwaseun Akinmulero, Rita Okonkwo, Oyewole Oyedele, Stacie Greby, Alash'le Abimiku, McPaul I J Okoye, Ray W Shiraishi","doi":"10.1016/j.ijid.2024.107309","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Evidence indicates that people living with HIV (PLHIV) are more impacted by COVID-19. The burden of SARS-CoV-2 infection among PLHIV is unknown in Nigeria.</p><p><strong>Methods: </strong>We conducted repeated cross-sectional SARS-CoV-2 serosurveys in 14 states and the Federal Capital Territory in Nigeria among PLHIV who had an HIV viral load (VL) test during April 2022 to January 2023. Evidence of SARS-CoV-2 immunoglobulin G (IgG) antibodies was assessed using a multiplex bead assay to measure IgG to spike (S), receptor binding domain (RBD), and nucleocapsid (N) proteins to identify potential infection and/or vaccination status.</p><p><strong>Results: </strong>Between April 2022 and January 2023, 47,614 remnant VL samples were included and tested for SARS-CoV-2 antibodies. Seroprevalence of SARS-CoV-2 infection, defined as IgG antibodies to spike and RBD591 [S+] and nucleocapsid [N+], (S+N+), ranged between 21.1% (95% confidence intervals [CI]: 11.4-31.8) in Ekiti State in January 2023 to 71.4% (95% CI 71.9-81.9) in Gombe State in November 2022, with overall steady trends within and between states over time, across age and sex.</p><p><strong>Conclusion: </strong>High rates of SARS-CoV-2 antibody seroprevalence among PLHIV in Nigeria were observed. This underscores the need to understand the association between HIV and SARS-CoV-2 to inform strategies to reduce the threat posed by COVID-19.</p>","PeriodicalId":14006,"journal":{"name":"International Journal of Infectious Diseases","volume":" ","pages":"107309"},"PeriodicalIF":4.8000,"publicationDate":"2024-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ijid.2024.107309","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: Evidence indicates that people living with HIV (PLHIV) are more impacted by COVID-19. The burden of SARS-CoV-2 infection among PLHIV is unknown in Nigeria.

Methods: We conducted repeated cross-sectional SARS-CoV-2 serosurveys in 14 states and the Federal Capital Territory in Nigeria among PLHIV who had an HIV viral load (VL) test during April 2022 to January 2023. Evidence of SARS-CoV-2 immunoglobulin G (IgG) antibodies was assessed using a multiplex bead assay to measure IgG to spike (S), receptor binding domain (RBD), and nucleocapsid (N) proteins to identify potential infection and/or vaccination status.

Results: Between April 2022 and January 2023, 47,614 remnant VL samples were included and tested for SARS-CoV-2 antibodies. Seroprevalence of SARS-CoV-2 infection, defined as IgG antibodies to spike and RBD591 [S+] and nucleocapsid [N+], (S+N+), ranged between 21.1% (95% confidence intervals [CI]: 11.4-31.8) in Ekiti State in January 2023 to 71.4% (95% CI 71.9-81.9) in Gombe State in November 2022, with overall steady trends within and between states over time, across age and sex.

Conclusion: High rates of SARS-CoV-2 antibody seroprevalence among PLHIV in Nigeria were observed. This underscores the need to understand the association between HIV and SARS-CoV-2 to inform strategies to reduce the threat posed by COVID-19.

2022 年 4 月至 2023 年 1 月对尼日利亚艾滋病病毒感染者进行 SARS-CoV-2 血清学监测。
目标:有证据表明,艾滋病毒感染者(PLHIV)受 COVID-19 的影响更大。尼日利亚艾滋病毒携带者感染 SARS-CoV-2 的情况尚不清楚:我们在尼日利亚 14 个州和联邦首都区对 2022 年 4 月至 2023 年 1 月期间接受过 HIV 病毒载量 (VL) 检测的 PLHIV 进行了重复横断面 SARS-CoV-2 血清调查。使用多重串珠检测法(MBA)评估 SARS-CoV-2 免疫球蛋白 G (IgG) 抗体的证据,检测 IgG 与尖峰蛋白 (S)、受体结合域 (RBD) 和核壳蛋白 (N) 的结合情况,以确定潜在的感染和/或疫苗接种状况:结果:2022 年 4 月至 2023 年 1 月期间,47,614 份残余 VL 样本被纳入并进行了 SARS-CoV-2 抗体检测。SARS-CoV-2感染的血清流行率(定义为尖头抗体和RBD591[S+]及核头壳[N+]的IgG抗体)从2023年1月埃基蒂州的21-1%(95% CI:11-4-31-8)到2022年11月贡贝州的71-4%(95% CI:71-9-81-9)不等,随着时间的推移,州内和各州之间在年龄和性别方面总体呈稳定趋势:结论:在尼日利亚的艾滋病毒携带者中,SARS-CoV-2 抗体血清阳性反应率很高。这突出表明,有必要了解艾滋病毒与 SARS-CoV-2 之间的关联,以便为减少 COVID-19 带来的威胁的战略提供信息。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
18.90
自引率
2.40%
发文量
1020
审稿时长
30 days
期刊介绍: International Journal of Infectious Diseases (IJID) Publisher: International Society for Infectious Diseases Publication Frequency: Monthly Type: Peer-reviewed, Open Access Scope: Publishes original clinical and laboratory-based research. Reports clinical trials, reviews, and some case reports. Focuses on epidemiology, clinical diagnosis, treatment, and control of infectious diseases. Emphasizes diseases common in under-resourced countries.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信